HALOZYME THERAPEUTICS IN Halozyme Therapeutics Inc is a security (CUSIP 40637HAG4) tracked across SEC portfolio filings. 11 registered fund positions totaling $53.6M via N-PORT as of 2026-05-29.
| Fund | Registrant | Value | % of fund |
|---|---|---|---|
| Calamos Market Neutral Income Fund | CALAMOS INVESTMENT TRUST/IL | $22.6M | 12.81% |
| NYLI MacKay Convertible Fund | NEW YORK LIFE INVESTMENTS FUNDS | $8.6M | 47.94% |
| Miller Convertible Bond Fund | Miller Investment Trust | $4.9M | 129.34% |
| Virtus Convertible & Income Fund | Virtus Convertible & Income Fund | $3.8M | 90.30% |
| Virtus Dividend, Interest & Premium Strategy Fund | Virtus Dividend, Interest & Premium Strategy Fund | $3.0M | 21.24% |
| Virtus Equity & Convertible Income Fund | Virtus Equity & Convertible Income Fund | $3.0M | 37.57% |
| Virtus Convertible & Income Fund II | Virtus Convertible & Income Fund II | $3.0M | 94.09% |
| Virtus Diversified Income & Convertible Fund | Virtus Diversified Income & Convertible Fund | $2.3M | 79.05% |
| Global Opportunities Portfolio | Global Opportunities Portfolio | $2.1M | 1.58% |
| BNY Mellon Core Plus Fund | BNY Mellon Absolute Insight Funds, Inc. | $195K | 0.77% |
| Franklin Alternative Strategies Fund | Franklin Alternative Strategies Funds | $30K | 0.50% |